Propanc Health Group Corp (OTCMKTS:PPCH) a expanding healthcare corporation concentrating on the advancement of proprietary treatments for cancer patients said fresh new insights have emerged into the advancement and spread of carcinomas. The insights are mentioned in the British Journal of Cancer by well-known researchers from the ‘University of Glasgow’. The insights may have remarkable implications for Propanc’s lead product, PRP, as a new way to control cancer spread, stated as metastasis. It is one of the main reasons of patient death from cancer.
In the publication, writer Professor Laura Machesky mentions how strict and regulated controls on cell increase and migration must for getting healthy states of tissues can result in deep problems when normal course is disturbed. The cancer spread from these tissues, termed as epithelial tissues, covering internal areas and organs in the human body, is known as carcinomas. The one major feature of carcinomas related with ‘metastatic spread’ and fierceness is the loss of function of epithelial integrity. Most of the times it is stated as epithelial to mesenchymal transition, a condition when cancer cells becomes invasive and motile, resulting into new tumors. The step is only a small start but she added the EMT may provide inputs that become a notable target for treating cancer.
What experts think?
Dr Julian Kenyon, Propanc’s CSO said that PRP uses two pancreatic proenzymes and that are trypsinogen and chymotrypsinogen. Both the enzymes in inactive state and when given to a patient, are believed to be activated at the tumor place. They have potential to change the cancer cell’s signaling lines. It, thus, forces cells to opt for normal behavior, following which cancer cells die naturally. Reversing the EMT method is a main target of Propanc’s PRP.
ON Thursday’s trading session, the stock price of Propanc surged more than 9% to close the trading session at $0.0200.